hydroxyurea and Local Neoplasm Recurrence
hydroxyurea has been researched along with Local Neoplasm Recurrence in 76 studies
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Previous in vitro and in vivo results suggested that hydroxyurea (HU) and verapamil could suppress meningioma growth individually and synergistically." | 9.22 | Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies. ( Barth, T; Burt, L; Dunson, W; Gillespie, DL; Hoang, N; Jensen, RL; Karsy, M, 2016) |
"Hydroxyurea (HU) is among the most widely used salvage therapies in progressive meningiomas." | 9.22 | Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). ( Brandes, A; Eoli, M; Faedi, M; Franceschi, E; Lombardi, G; Mazza, E; Reni, M; Zanon, S, 2016) |
"We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma." | 9.16 | Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. ( Coan, A; Desjardins, A; Drappatz, J; Friedman, HS; Gururangan, S; Herndon, JE; Lipp, ES; McLendon, RE; Norden, AD; Norfleet, JA; Peters, KB; Reardon, DA; Sampson, JH; Vredenburgh, JJ; Wen, PY, 2012) |
"Although tumor regression appears uncommon, these results indicate that hydroxyurea may arrest progression of unresectable or recurrent benign meningiomas." | 9.10 | Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. ( Abrey, LE; Cruz, CR; Gentili, F; Hariharan, S; Macdonald, DR; Mason, WP, 2002) |
"In this paper the authors present the first evidence that meningiomas respond to treatment with hydroxyurea." | 9.08 | Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. ( Anders, M; Fahlbusch, R; Kiesewetter, F; Koch, UH; Marschalek, R; Rittig, MG; Schrell, UM, 1997) |
"To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
"The aim of this study was to evaluate the efficacy and toxicity profile of the cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine (CHAMOC) regimen in the treatment of high-risk gestational trophoblastic neoplasia (GTN)." | 7.81 | Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia. ( Chan, KK; Chu, MM; Ma, Y; Ngan, HY; Tse, KY, 2015) |
"Hydroxyurea (HU), an orally administered chemotherapy, has become the de facto standard therapeutic agent in patients with surgically and radiation refractory meningiomas based on a limited literature." | 7.77 | Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. ( Chamberlain, MC; Johnston, SK, 2011) |
"Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 7.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
"Forty-seven patients with medulloblastoma were treated postoperatively with procarbazine, followed by craniospinal radiation therapy in combination with hydroxyurea." | 7.67 | Treatment of medulloblastoma with procarbazine, hydroxyurea, and reduced radiation doses to whole brain and spine. ( Davis, RL; Edwards, MS; Fulton, D; Levin, VA; Liu, HC; Rodriguez, LA; Silver, P; Wara, W; Wilson, CB, 1988) |
"Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 7.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
"4 Gy) and concurrent HU, administered for a median time of three months with a daily dosage of 20 mg/kg." | 6.43 | Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. ( Fahlbusch, R; Ganslandt, O; Grabenbauer, GG; Hahn, BM; Sauer, R; Schrell, UM, 2005) |
"Hydroxyurea was given orally at an initial dose of 20 mg/kg/day (escalated up to 30 mg/kg/day as necessary, if well tolerated)." | 5.51 | Evidence of hydroxyurea activity in children with pretreated desmoid-type fibromatosis: A new option in the armamentarium of systemic therapies. ( Affinita, MC; Bisogno, G; Casanova, M; Chiaravalli, S; Corradini, N; Ferrari, A; Meazza, C; Orbach, D, 2019) |
"Hydroxyurea was well tolerated although two patients ceased therapy because of skin rashes." | 5.31 | Treatment of high risk or recurrent meningiomas with hydroxyurea. ( Ashley, DL; Cher, L; Rosenthal, MA, 2002) |
"Short-term treatment of meningioma cell cultures with hydroxyurea for 24 to 48 hours resulted in discrete oligonucleosomal fragments (DNA ladder), another characteristic sign of apoptosis." | 5.30 | Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. ( Anders, M; Fahlbusch, R; Kiesewetter, F; Koch, UH; Marschalek, R; Rittig, MG; Schrell, UM, 1997) |
"Previous in vitro and in vivo results suggested that hydroxyurea (HU) and verapamil could suppress meningioma growth individually and synergistically." | 5.22 | Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies. ( Barth, T; Burt, L; Dunson, W; Gillespie, DL; Hoang, N; Jensen, RL; Karsy, M, 2016) |
"Hydroxyurea (HU) is among the most widely used salvage therapies in progressive meningiomas." | 5.22 | Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). ( Brandes, A; Eoli, M; Faedi, M; Franceschi, E; Lombardi, G; Mazza, E; Reni, M; Zanon, S, 2016) |
"We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma." | 5.16 | Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. ( Coan, A; Desjardins, A; Drappatz, J; Friedman, HS; Gururangan, S; Herndon, JE; Lipp, ES; McLendon, RE; Norden, AD; Norfleet, JA; Peters, KB; Reardon, DA; Sampson, JH; Vredenburgh, JJ; Wen, PY, 2012) |
"Although tumor regression appears uncommon, these results indicate that hydroxyurea may arrest progression of unresectable or recurrent benign meningiomas." | 5.10 | Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. ( Abrey, LE; Cruz, CR; Gentili, F; Hariharan, S; Macdonald, DR; Mason, WP, 2002) |
"In this paper the authors present the first evidence that meningiomas respond to treatment with hydroxyurea." | 5.08 | Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. ( Anders, M; Fahlbusch, R; Kiesewetter, F; Koch, UH; Marschalek, R; Rittig, MG; Schrell, UM, 1997) |
"To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
"The aim of this study was to evaluate the efficacy and toxicity profile of the cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine (CHAMOC) regimen in the treatment of high-risk gestational trophoblastic neoplasia (GTN)." | 3.81 | Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia. ( Chan, KK; Chu, MM; Ma, Y; Ngan, HY; Tse, KY, 2015) |
"Hydroxyurea (HU), an orally administered chemotherapy, has become the de facto standard therapeutic agent in patients with surgically and radiation refractory meningiomas based on a limited literature." | 3.77 | Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. ( Chamberlain, MC; Johnston, SK, 2011) |
"Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 3.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
"Forty-seven patients with medulloblastoma were treated postoperatively with procarbazine, followed by craniospinal radiation therapy in combination with hydroxyurea." | 3.67 | Treatment of medulloblastoma with procarbazine, hydroxyurea, and reduced radiation doses to whole brain and spine. ( Davis, RL; Edwards, MS; Fulton, D; Levin, VA; Liu, HC; Rodriguez, LA; Silver, P; Wara, W; Wilson, CB, 1988) |
"Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 3.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
"Patients with recurrent squamous cell carcinoma or a second primary arising in a previously irradiated field were eligible." | 2.73 | Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. ( Ang, KK; Harris, J; Machtay, M; Meredith, R; Rotman, M; Schultz, C; Spanos, W; Spencer, SA; Wheeler, RH, 2008) |
"The imatinib mesylate dose was 500 mg twice a day for patients on enzyme inducing anti-epileptic drugs (EIAEDs) and 400 mg once a day for those not on EIAEDs." | 2.73 | Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. ( Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Salvado, A; Sampson, JH; Sathornsumetee, S; Vredenburgh, JJ, 2007) |
"The purpose of this study was to analyze the tolerance and efficacy of full dose reirradiation combined with chemotherapy in patients with head and neck carcinoma (HNC) with a high risk of recurrence after salvage surgery." | 2.70 | Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. ( Bobin, S; Bourhis, J; De Crevoisier, R; Domenge, C; Eschwege, F; Janot, F; Koscielny, S; Luboinski, B; Lusinchi, A; Wibault, P, 2001) |
"Thrombocytosis was not found to be a prognostic factor in patients with positive pelvic nodes." | 2.69 | The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. ( Anderson, LL; Donohue, KA; Heller, PB; Hernandez, E; Stehman, FB, 2000) |
"The head and neck cancer program at the University of Chicago has reported encouraging results with concomitant 5-fluorouracil, hydroxyurea, and radiation administered every other week to patients with locally advanced or recurrent disease." | 2.68 | Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. ( Haraf, DJ; List, M; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME, 1997) |
"Thirty-nine patients with head and neck cancer were entered into Phase I-II study of simultaneous radiation therapy with continuous infusion fluorouracil at 800 mg/m2/day and escalating doses of hydroxyurea." | 2.67 | Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1991) |
"4 Gy) and concurrent HU, administered for a median time of three months with a daily dosage of 20 mg/kg." | 2.43 | Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. ( Fahlbusch, R; Ganslandt, O; Grabenbauer, GG; Hahn, BM; Sauer, R; Schrell, UM, 2005) |
"The common clinical presentations of head and neck cancer include early (stage I or II) disease, locally or regionally advanced (stage III or IV, M0) disease, and recurrent or metastatic disease (< 5% of patients)." | 2.40 | Oral 5-FU alternatives for the treatment of head and neck cancer. ( Brockstein, BE; Haraf, DJ; Humerickhouse, R; Vokes, EE, 1998) |
"Hydroxyurea was given orally at an initial dose of 20 mg/kg/day (escalated up to 30 mg/kg/day as necessary, if well tolerated)." | 1.51 | Evidence of hydroxyurea activity in children with pretreated desmoid-type fibromatosis: A new option in the armamentarium of systemic therapies. ( Affinita, MC; Bisogno, G; Casanova, M; Chiaravalli, S; Corradini, N; Ferrari, A; Meazza, C; Orbach, D, 2019) |
"From 09/1991 - 06/2007, 24 high-risk salivary gland cancer patients were treated with surgery, followed by adjuvant chemoradiotherapy for high-risk pathologic features including, perineural involvement, nodal involvement, positive margins, or T3/T4 tumors." | 1.37 | Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. ( Blair, EA; Cohen, EE; Haraf, DJ; Pederson, AW; Portugal, L; Salama, JK; Seiwert, T; Stenson, KM; Villaflor, VM; Vokes, EE; Witt, ME, 2011) |
"Hydroxyurea was well tolerated although two patients ceased therapy because of skin rashes." | 1.31 | Treatment of high risk or recurrent meningiomas with hydroxyurea. ( Ashley, DL; Cher, L; Rosenthal, MA, 2002) |
"Short-term treatment of meningioma cell cultures with hydroxyurea for 24 to 48 hours resulted in discrete oligonucleosomal fragments (DNA ladder), another characteristic sign of apoptosis." | 1.30 | Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. ( Anders, M; Fahlbusch, R; Kiesewetter, F; Koch, UH; Marschalek, R; Rittig, MG; Schrell, UM, 1997) |
"Reirradiation of head and neck cancer with 5-fluorouracil and hydroxyurea offers acceptable acute toxicity and minimal late effects." | 1.30 | Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. ( Beenken, SW; Conner, W; Meredith, RF; Peters, GE; Salter, MM; Smith, J; Spencer, SA; Wheeler, RH, 1999) |
"Head and neck cancer locally recurrent after previous irradiation and surgery presents a difficult management problem." | 1.28 | Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation. ( Kim, RY; Meredith, RF; Peters, GE; Salter, MM; Spencer, SA; Weppelmann, B; Wheeler, RH, 1992) |
"Hydroxyurea is an active single agent in squamous cell cancer of the head and neck." | 1.28 | Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. ( Haraf, DJ; Panje, WR; Schilsky, RL; Vokes, EE; Weichselbaum, RR, 1992) |
"Sixty-six patients with advanced head and neck cancer 57 of whom had failed to respond to prior irradiation, were treated according to two protocols." | 1.26 | [Chemotherapy of advanced head and neck cancer with a combination of bleomycin, vincristine, methotrexate and hydroxyuree or cis-dichloro-diamino-platinium. Analysis of local and general parameters of prognosis (author's transl)]. ( Asselin, B; Bataini, JP; Brugère, J; Garcia-Giralt, E; Jaulerry, M; Jouve, M; Palangie, T; Pouillart, P, 1980) |
Research
Studies (76)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 26 (34.21) | 18.7374 |
1990's | 18 (23.68) | 18.2507 |
2000's | 18 (23.68) | 29.6817 |
2010's | 13 (17.11) | 24.3611 |
2020's | 1 (1.32) | 2.80 |
Authors
Authors | Studies |
---|---|
Rubin, A | 1 |
Haroon, A | 1 |
Rao, BK | 1 |
Firoz, BF | 1 |
Parasramka, S | 1 |
Talari, G | 1 |
Rosenfeld, M | 1 |
Guo, J | 1 |
Villano, JL | 1 |
Ferrari, A | 1 |
Orbach, D | 1 |
Affinita, MC | 1 |
Chiaravalli, S | 1 |
Corradini, N | 1 |
Meazza, C | 1 |
Bisogno, G | 1 |
Casanova, M | 1 |
Chu, MM | 1 |
Ma, Y | 1 |
Tse, KY | 1 |
Chan, KK | 1 |
Ngan, HY | 1 |
Karsy, M | 1 |
Hoang, N | 1 |
Barth, T | 1 |
Burt, L | 1 |
Dunson, W | 1 |
Gillespie, DL | 1 |
Jensen, RL | 1 |
Mazza, E | 1 |
Brandes, A | 1 |
Zanon, S | 1 |
Eoli, M | 1 |
Lombardi, G | 1 |
Faedi, M | 1 |
Franceschi, E | 1 |
Reni, M | 1 |
Dresemann, G | 2 |
Weller, M | 1 |
Rosenthal, MA | 2 |
Wedding, U | 1 |
Wagner, W | 1 |
Engel, E | 1 |
Heinrich, B | 1 |
Mayer-Steinacker, R | 1 |
Karup-Hansen, A | 1 |
Fluge, O | 1 |
Nowak, A | 1 |
Mehdorn, M | 1 |
Schleyer, E | 1 |
Krex, D | 1 |
Olver, IN | 1 |
Steinbach, JP | 1 |
Hosius, C | 1 |
Sieder, C | 1 |
Sorenson, G | 1 |
Parker, R | 1 |
Nikolova, Z | 1 |
Paulsson, J | 1 |
Lindh, MB | 1 |
Jarvius, M | 1 |
Puputti, M | 1 |
Nistér, M | 1 |
Nupponen, NN | 1 |
Paulus, W | 1 |
Söderberg, O | 1 |
von Deimling, A | 1 |
Joensuu, H | 1 |
Ostman, A | 1 |
Hasselblatt, M | 1 |
Chamberlain, MC | 1 |
Johnston, SK | 1 |
Choe, KS | 1 |
Haraf, DJ | 11 |
Solanki, A | 1 |
Cohen, EE | 3 |
Seiwert, TY | 1 |
Stenson, KM | 4 |
Blair, EA | 2 |
Portugal, L | 3 |
Villaflor, VM | 2 |
Witt, ME | 5 |
Vokes, EE | 12 |
Salama, JK | 3 |
Pederson, AW | 1 |
Seiwert, T | 1 |
Reardon, DA | 3 |
Norden, AD | 1 |
Desjardins, A | 3 |
Vredenburgh, JJ | 3 |
Herndon, JE | 3 |
Coan, A | 2 |
Sampson, JH | 2 |
Gururangan, S | 3 |
Peters, KB | 2 |
McLendon, RE | 2 |
Norfleet, JA | 1 |
Lipp, ES | 2 |
Drappatz, J | 1 |
Wen, PY | 1 |
Friedman, HS | 3 |
McLendon, R | 1 |
Sathornsumetee, S | 2 |
Rich, JN | 2 |
Janney, D | 1 |
Golden, DW | 1 |
Rudra, S | 1 |
Nwizu, T | 1 |
Blair, E | 1 |
Mason, WP | 1 |
Gentili, F | 1 |
Macdonald, DR | 1 |
Hariharan, S | 1 |
Cruz, CR | 1 |
Abrey, LE | 2 |
Spencer, S | 1 |
Wheeler, R | 1 |
Peters, G | 1 |
Meredith, R | 2 |
Beenken, S | 1 |
Nabel, L | 1 |
Wooten, A | 1 |
Soong, SJ | 1 |
Salter, M | 1 |
Petti, MC | 1 |
Tafuri, A | 1 |
Latagliata, R | 1 |
Aloe Spiriti, MA | 1 |
Montefusco, E | 1 |
Mancini, M | 1 |
Meloni, G | 1 |
Petrucci, MT | 1 |
Spadea, A | 1 |
Redi, R | 1 |
Alimena, G | 1 |
Mandelli, F | 1 |
Faivre, S | 1 |
Marti, A | 1 |
Rixe, O | 1 |
Janot, F | 2 |
Julieron, M | 1 |
Gatineau, M | 1 |
Temam, S | 1 |
Armand, JP | 1 |
Domenge, C | 2 |
Luboinski, B | 2 |
Raymond, E | 1 |
Hahn, BM | 1 |
Schrell, UM | 3 |
Sauer, R | 1 |
Fahlbusch, R | 3 |
Ganslandt, O | 1 |
Grabenbauer, GG | 1 |
Chmura, SJ | 1 |
Milano, MT | 1 |
Kao, J | 1 |
Cramer, P | 1 |
Thomale, UW | 1 |
Okuducu, AF | 1 |
Lemke, AJ | 1 |
Stockhammer, F | 1 |
Woiciechowsky, C | 1 |
Quinn, JA | 1 |
Friedman, AH | 1 |
Provenzale, JM | 1 |
Dowell, JM | 1 |
Salvado, A | 1 |
Shah, GD | 1 |
Silver, JS | 1 |
Rosenfeld, SS | 1 |
Gavrilovic, IT | 1 |
Lassman, AB | 1 |
Spencer, SA | 3 |
Harris, J | 1 |
Wheeler, RH | 3 |
Machtay, M | 1 |
Schultz, C | 1 |
Spanos, W | 1 |
Rotman, M | 1 |
Ang, KK | 1 |
Stehlin, JS | 1 |
Hills, WJ | 1 |
Rufino, C | 1 |
Pouillart, P | 1 |
Palangie, T | 1 |
Garcia-Giralt, E | 1 |
Jouve, M | 1 |
Bataini, JP | 1 |
Jaulerry, M | 1 |
Brugère, J | 1 |
Asselin, B | 1 |
Vogl, SE | 1 |
Camacho, F | 1 |
Kaplan, BH | 1 |
Lerner, H | 1 |
Cinberg, J | 1 |
Hill, GJ | 1 |
Krementz, ET | 1 |
Hill, HZ | 1 |
Schmidt, JD | 1 |
Scott, WW | 1 |
Gibbons, R | 1 |
Johnson, DE | 1 |
Prout, GR | 1 |
Loening, S | 1 |
Soloway, M | 1 |
deKernion, JB | 1 |
Pontes, JE | 1 |
Slack, NH | 1 |
Murphy, GP | 2 |
Shields, TW | 1 |
Higgins, GA | 1 |
Humphrey, EW | 1 |
Matthews, MJ | 1 |
Keehn, RJ | 1 |
Levin, VA | 5 |
Wilson, CB | 2 |
Vestnys, PS | 1 |
Stenson, K | 3 |
Stupp, R | 1 |
Malone, D | 1 |
Levin, J | 1 |
Weichselbaum, RR | 6 |
Sneed, PK | 1 |
Gutin, PH | 1 |
Larson, DA | 1 |
Malec, MK | 1 |
Phillips, TL | 1 |
Prados, MD | 2 |
Scharfen, CO | 1 |
Weaver, KA | 1 |
Wara, WM | 1 |
Currie, JL | 1 |
Blessing, JA | 1 |
McGehee, R | 1 |
Soper, JT | 1 |
Berman, M | 1 |
Kyritsis, AP | 1 |
Yung, WK | 1 |
Jaeckle, KA | 1 |
Bruner, J | 1 |
Gleason, MJ | 1 |
Ictech, SE | 1 |
Flowers, A | 1 |
List, M | 2 |
Rittig, MG | 2 |
Anders, M | 2 |
Kiesewetter, F | 2 |
Marschalek, R | 2 |
Koch, UH | 2 |
Cusimano, MD | 1 |
Brockstein, BE | 1 |
Humerickhouse, R | 1 |
Peters, GE | 2 |
Beenken, SW | 1 |
Meredith, RF | 2 |
Smith, J | 1 |
Conner, W | 1 |
Salter, MM | 2 |
Haie-Meder, C | 1 |
Fervers, B | 1 |
Chauvergne, J | 1 |
Fondrinier, E | 1 |
Lhommé, C | 1 |
Guastalla, JP | 1 |
Resbeut, M | 1 |
Schaefer, U | 1 |
Micke, O | 1 |
Schueller, P | 1 |
Willich, N | 1 |
Hernandez, E | 1 |
Donohue, KA | 1 |
Anderson, LL | 1 |
Heller, PB | 1 |
Stehman, FB | 1 |
Kies, MS | 1 |
Rosen, F | 1 |
Brockstein, B | 1 |
Chung, T | 1 |
Mittal, BB | 1 |
Pelzer, H | 1 |
Rademaker, A | 1 |
Weichselbaum, R | 1 |
De Crevoisier, R | 1 |
Wibault, P | 1 |
Koscielny, S | 1 |
Lusinchi, A | 1 |
Bobin, S | 1 |
Eschwege, F | 1 |
Bourhis, J | 1 |
Fiorillo, A | 1 |
Maggi, G | 1 |
Martone, A | 1 |
Migliorati, R | 1 |
D'Amore, R | 1 |
Alfieri, E | 1 |
Greco, N | 1 |
Cirillo, S | 1 |
Marano, I | 1 |
Maury, S | 1 |
Belhadj, K | 1 |
Chami, I | 1 |
Kuentz, M | 1 |
Cordonnier, C | 1 |
Bories, D | 1 |
Wassmann, B | 1 |
Klein, SA | 1 |
Scheuring, U | 1 |
Pfeifer, H | 1 |
Martin, H | 1 |
Gschaidmeier, H | 1 |
Hoelzer, D | 1 |
Ottmann, OG | 1 |
Ashley, DL | 1 |
Cher, L | 1 |
Kapoor, N | 1 |
Keever, CA | 1 |
Hsu, SH | 1 |
Copelan, EA | 1 |
Tutschka, PJ | 1 |
McGinn, CJ | 1 |
Kinsella, TJ | 1 |
Weppelmann, B | 1 |
Kim, RY | 1 |
Panje, WR | 3 |
Schilsky, RL | 2 |
Abele, R | 1 |
Honegger, HP | 1 |
Grossenbacher, R | 1 |
Mermillod, B | 1 |
Kaplan, E | 1 |
Gervasi, A | 1 |
Wolfensberger, M | 1 |
Lehmann, W | 1 |
Cavalli, F | 1 |
Grant, HR | 1 |
Clifford, P | 1 |
Piver, M | 1 |
Khalil, M | 1 |
Emrich, LJ | 1 |
Belani, CP | 1 |
Eisenberger, M | 1 |
Van Echo, D | 1 |
Hiponia, D | 1 |
Aisner, J | 1 |
Pendergrass, TW | 1 |
Milstein, JM | 1 |
Geyer, JR | 1 |
Mulne, AF | 1 |
Kosnik, EJ | 1 |
Morris, JD | 1 |
Heideman, RL | 1 |
Ruymann, FB | 1 |
Stuntz, JT | 1 |
Bleyer, WA | 1 |
Moran, WJ | 1 |
Awan, AM | 1 |
Guarnieri, CM | 1 |
Rodriguez, LA | 2 |
Edwards, MS | 2 |
Wara, W | 1 |
Liu, HC | 1 |
Fulton, D | 2 |
Davis, RL | 1 |
Silver, P | 2 |
Prados, M | 1 |
Levin, V | 1 |
Bezwoda, WR | 1 |
Nissenbaum, M | 1 |
Derman, DP | 1 |
Abdi, EA | 1 |
Hanson, J | 1 |
McPherson, TA | 1 |
Simmonds, WP | 1 |
Stephens, FO | 1 |
Watne, AL | 1 |
Covey, TH | 1 |
Carter, SK | 1 |
Smith, JP | 1 |
Rutledge, F | 1 |
Burns, BC | 1 |
Soffar, S | 1 |
Hussey, DH | 1 |
Samuels, ML | 1 |
Kaufman, JJ | 1 |
Clinical Trials (3)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas[NCT00706810] | Phase 2 | 8 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma[NCT00354913] | Phase 2 | 21 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation[NCT00970502] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Median Progression-free Survival Rates of the Treatment Population.
Response and progression will be evaluated in this study using measurements from the MRI/CT scans. Measurements will be made of the image slice with the largest cross sectional area. Two orthogonal measures will be made to determine maximal AP and lateral dimensions. Progression of disease will be defined as a greater than 25% increase of largest cross sectional area by two orthogonal measurements, taking as reference the smallest sum recorded since the treatment started or the appearance of one or more new lesions. (NCT00706810)
Timeframe: 31 months
Intervention | months (Median) |
---|---|
All Participants | 8.0 |
Number of Participants Experiencing Serious Adverse Events Including But Not Limited to Hospitalizations, Deaths Related to Treatment, or Other Incapacitating Conditions.
Adverse Events assessed in accordance with CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 3.0. (NCT00706810)
Timeframe: two years
Intervention | participants (Number) |
---|---|
All Groups | 0 |
Median Overall Survival (OS)
Time in months from the start of study treatment to date of death due to any cause. Patients alive at last follow-up are censored as of that follow-up date. Median OS was estimated using a Kaplan-Meier curve. (NCT00354913)
Timeframe: From the date of study treatment initiation to the date of death from any cause, assessed up to 69 months.
Intervention | months (Median) |
---|---|
Imatinib Mesylate+Hydroxyurea | 66 |
Median Progression-free Survival (PFS)
Time in months from the start of study treatment to the date of first progression according to Macdonald criteria, or to death due to any cause. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median PFS was estimated using a Kaplan-Meier curve. (NCT00354913)
Timeframe: From the date of study treatment initiation to the date of the first documented progression or death from any cause, whichever came first, assessed up to 69 months.
Intervention | months (Median) |
---|---|
Imatinib Mesylate+Hydroxyurea | 7 |
Objective Response Rate
Percentage of participants with an objective response (complete response or partial response). Per modified Macdonald criteria and assessed by MRI, complete response (CR) was the disappearance of all target lesions and partial response (PR) was a ≥50% decrease in the sum of the longest diameter of target lesions. Objective response = CR+PR. (NCT00354913)
Timeframe: 69 Months
Intervention | percentage of participants (Number) |
---|---|
Imatinib Mesylate+Hydroxyurea | 0 |
Progression-free Survival at 6 Months
Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or death due to any cause. (NCT00354913)
Timeframe: From the date of study treatment initiation to the date of the first documented progression or death from any cause, whichever came first, assessed up to 69 months. For each participant, PFS was assessed at 6 months after treatment initiation.
Intervention | percentage of participants (Number) |
---|---|
Imatinib Mesylate+Hydroxyurea | 61.9 |
Toxicity
Number of participants with acute and late toxicity (NCT00970502)
Timeframe: 30 DAYS
Intervention | participants (Number) |
---|---|
Celecoxib 200mg | 0 |
Celecoxib 400mg | 1 |
Celecoxib 600mg | 2 |
Clinical Response
Response to Concurrent Erlotinib, Celecoxib, and Reirradiation according to Response Evaluation Criteria in Solid Tumors - Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT00970502)
Timeframe: 20 months
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
Complete Response(CR) | Pathologic partial response (pPR) | Progressive disease (PD) | No evidence of disease (NED) | |
Erlotinib + Celecoxib | 6 | 1 | 5 | 2 |
Locoregional Control, Progression-free Survival, Overall Survival and Late Toxicity
At a median follow-up of 11 months, the 1 year locoregional control, progression-free survival, and overall survival rates. (NCT00970502)
Timeframe: 1 year
Intervention | percentage of participants (Number) | |||
---|---|---|---|---|
locoregional control | progress-free survival | overall survival rates | long term toxicity | |
Erlotinib + Celecoxib | 60 | 37 | 55 | 0 |
Locoregional Progression
Patients with locoregional and/or distant progression (NCT00970502)
Timeframe: 20 months
Intervention | participants (Number) | ||||
---|---|---|---|---|---|
free of disease | isolated locoregional progression | isolated distant progression | both locoregional and distant progression | no evidence of disease, died of comorbid illness | |
Erlotinib + Celecoxib | 4 | 4 | 2 | 1 | 3 |
Reviews
7 reviews available for hydroxyurea and Local Neoplasm Recurrence
Article | Year |
---|---|
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Disease Progres | 2005 |
The role of paclitaxel in the treatment of head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1995 |
Oral 5-FU alternatives for the treatment of head and neck cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1998 |
[Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1999 |
The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation.
Topics: Animals; Cell Division; Fluorouracil; Humans; Hydroxyurea; Neoplasm Recurrence, Local; Neoplasms; Ra | 1992 |
Chemotherapy of primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Brain Stem; Child; Efl | 1985 |
Trials
27 trials available for hydroxyurea and Local Neoplasm Recurrence
Article | Year |
---|---|
Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biologi | 2016 |
Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; | 2016 |
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Brai | 2010 |
Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Drug Resistance, Neopla | 2011 |
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease | 2012 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Humans; Hydroxyurea; Karnofsky Perf | 2002 |
Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2003 |
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamide | 2007 |
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Bone Marrow Di | 2007 |
Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1984 |
Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung.
Topics: Carcinoma; Clinical Trials as Topic; Humans; Hydroxyurea; Lomustine; Lung Neoplasms; Male; Neoplasm | 1982 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain; Brain Neoplasms; | 1994 |
Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Etopo | 1996 |
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1996 |
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1997 |
Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
Topics: Adult; Antineoplastic Agents; Female; Humans; Hydroxyurea; Magnetic Resonance Imaging; Male; Meninge | 1997 |
The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Disease-Free Survival | 2000 |
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2001 |
Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
[Chemotherapy of advanced prostate cancer].
Topics: Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Diethylstilbestrol; Drug Eval | 1977 |
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 1991 |
A randomized study of methotrexate, bleomycin, hydroxyurea with versus without cisplatin in patients with previously untreated and recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1987 |
Hydroxyurea plus pelvic irradiation versus placebo plus pelvic irradiation in nonsurgically staged stage IIIB cervical cancer.
Topics: Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Combined Modality Therapy; Double-Blind Method; Fe | 1989 |
Treatment of metastatic and recurrent cervix cancer with chemotherapy: a randomised trial comparing hydroxyurea with cisdiamminedichloro-platinum plus methotrexate.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trial | 1986 |
Other Studies
42 other studies available for hydroxyurea and Local Neoplasm Recurrence
Article | Year |
---|---|
Utility of Optical Imaging in a Patient With Recurrent, Multifocal Hydroxyurea-Associated Basal Cell Carcinoma.
Topics: Carcinoma, Basal Cell; Female; Head and Neck Neoplasms; Humans; Hydroxyurea; Middle Aged; Neoplasm R | 2022 |
Evidence of hydroxyurea activity in children with pretreated desmoid-type fibromatosis: A new option in the armamentarium of systemic therapies.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Disease Progression; Female; Fibr | 2019 |
Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Female; Gesta | 2015 |
Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Disease-Free Survival; Drug Administrati | 2011 |
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Ch | 2011 |
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; Fl | 2011 |
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2013 |
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Cytogenetic Analysis; Dose-Response Relat | 2003 |
Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2005 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality | 2006 |
An atypical spinal meningioma with CSF metastasis: fatal progression despite aggressive treatment. Case report.
Topics: Adult; Antineoplastic Agents; Cervical Vertebrae; Decompression, Surgical; Disease Progression; Fata | 2005 |
Disseminated melanoma. Biologic behavior and treatment.
Topics: Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Dactinomycin; Fluorouracil; Humans; Hydrazine | 1967 |
[Chemotherapy of advanced head and neck cancer with a combination of bleomycin, vincristine, methotrexate and hydroxyuree or cis-dichloro-diamino-platinium. Analysis of local and general parameters of prognosis (author's transl)].
Topics: Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Head and Neck | 1980 |
Hydroxyurea fails to improve the results of MBD chemotherapy in cancer of the head and neck, but reduces toxicity.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug | 1983 |
Chemotherapy programs of the National Prostatic Cancer Project (NPCP).
Topics: Antineoplastic Agents; Cyclophosphamide; Dacarbazine; Diethylstilbestrol; Drug Evaluation; Drug Ther | 1980 |
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr | 1996 |
Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; DNA Fragmentation; Dose-Respon | 1997 |
Hydroxyurea for treatment of meningioma.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Lo | 1998 |
Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1999 |
Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2000 |
Shunt-related abdominal metastases in an infant with medulloblastoma: long-term remission by systemic chemotherapy and surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cerebellar Neoplasms; Combi | 2001 |
Autologous reconstitution combined with durable leukemic remission after allogeneic BMT for CML: absence of persistence of a donor-derived T cell effector population.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Bone Marrow T | 2001 |
Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Marrow Transplantation; C | 2001 |
Treatment of high risk or recurrent meningiomas with hydroxyurea.
Topics: Adult; Aged; Antineoplastic Agents; Exanthema; Female; Humans; Hydroxyurea; Male; Meningeal Neoplasm | 2002 |
Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle | 1992 |
Prolonged remission of accelerated phase Philadelphia chromosome negative chronic myeloid leukemia following autologous recovery of normal hematopoietic elements after busulfan/cyclophosphamide and allogeneic marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantat | 1992 |
Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation.
Topics: Adult; Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Head and | 1992 |
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
Topics: Administration, Oral; Bone Marrow; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fluorouracil; H | 1992 |
Postcricoid carcinoma: a retrospective study of 13 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1985 |
Phase II study of caracemide in advanced or recurrent non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis-Related Groups; Drug Evaluation; Female; Huma | 1987 |
Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Cisplatin; Comb | 1987 |
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1988 |
Treatment of medulloblastoma with procarbazine, hydroxyurea, and reduced radiation doses to whole brain and spine.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain; Cerebellar Neoplasms; Child; Comb | 1988 |
Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Chil | 1988 |
Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carmustine; Com | 1987 |
Chemotherapy in recurrent heat and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Drug Thera | 1974 |
Combined chemotherapy, radiotherapy, and surgery in the treatment of advanced but localized solid malignant tumours.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cystadenocarcinoma; Drug Th | 1974 |
Hormones, chemotherapy, and the breast cancer patient.
Topics: Administration, Oral; Adrenalectomy; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Female; Fluoro | 1972 |
Some thoughts on surgical adjuvant studies in lung cancer.
Topics: Alkylating Agents; Antineoplastic Agents; Carcinoma, Bronchogenic; Cyclophosphamide; Drug Combinatio | 1973 |
Systemic chemotherapy for carcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Fema | 1967 |
Combined hydroxyurea and radiotherapy: a new dosage schedule.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Head; Head and Neck Neoplasms; | 1972 |
Treatment of carcinoma of the bladder with combined radiotherapy, chemotherapy, and surgery.
Topics: Animals; Cricetinae; Female; Fluorouracil; Humans; Hydroxyurea; Male; Mitomycins; Neoplasm Metastasi | 1969 |